Rapamycin inhibits the growth of glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The molecular target of rapamycin (mTOR) pathway is frequently upregulated in glioblastoma (GBM), correlating with tumor growth, stem cell activity, and recurrence.
• Rapamycin, a potent mTOR inhibitor and autophagy inducer, has shown promise in preclinical GBM studies, but its efficacy in patient-derived cells and in vivo models requires further investigation.

Purpose of the Study:

• To evaluate the efficacy of rapamycin in inhibiting glioblastoma cell growth using both established cell lines and primary patient-derived cells.
• To assess the in vivo therapeutic effects of rapamycin on glioblastoma xenografts in mice, focusing on tumor volume reduction and survival extension.

Main Methods:

• Rapamycin was tested at various doses in vitro on U87Mg glioblastoma cell lines and primary cell cultures from GBM patients.
• The therapeutic potential of rapamycin was evaluated in vivo using nude mouse models with brain xenografts derived from glioblastoma.

Main Results:

• Rapamycin demonstrated significant inhibition of cell growth at doses as low as 10nm in both U87Mg cells and primary GBM cultures.
• In vivo administration of rapamycin in brain xenografts nearly doubled mouse survival time and reduced tumor volume by over 95%.

Conclusions:

• Rapamycin exhibits potent anti-tumor activity against glioblastoma in both in vitro and in vivo models.
• These findings support rapamycin as a potential adjuvant therapy for glioblastoma, warranting further clinical investigation.